New Clinical Study by Agios Pharmaceutical to Sign Up Now

Dear Sickle Cell Warriors and Allies,

Whether you are a Sickle Cell Warrior, caregiver, community outreach member, or healthcare provider—Agios Pharmaceuticals hopes you were empowered and energized by this year’s Foundation for Sickle Cell Disease Research (FSCDR) conference.

As a reminder, Agios has recently launched the RISE UP clinical trial.

This phase 2/3, double-blind, placebo-controlled study is open to patients with sickle cell disease, ages 16 and older. Please consider learning more about this trial and sharing information about RISE UP with others in the #SickleCellWarrior community.

The initial 3-month study will evaluate the efficacy and safety of mitapivat in challenging sickle cell pain crises and anemia.

For more information, including whether RISE UP may or may not be a good fit, visit: RiseUpStudy.com
Access the latest enrollment and study center information at: clinicaltrials.gov/ct2/show/NCT05031780
Learn about mitapivat and how it is thought to work at: RiseUpStudy.com/about-mitapivat
Mitapivat is not approved for the treatment of sickle cell disease. If you would like answers to specific questions, please contact Agios Medical Information at 1-833-228-8474, Mon-Fri, 9 am to 7 pm ET, or email medinfo@agios.com.

Agios supports continued advancement for the Sickle Cell Warrior community.